Ixazomib Citrate (MLN9708) immediately hydrolyzed to Ixazomib (MLN2238), the biologically active form, on exposure to aqueous solutions or plasma. Ixazomib (MLN2238) inhibits the chymotrypsin-like proteolytic (?5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to ?1 and little activity to ?2. Ixazomib (MLN2238) induces autophagy. Phase 3. *For Research & Development use only. Product is not intended for drug, household, or human consumption.